-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ocumension Therapeutics' (HKG:1477) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged HK$632m Last Week
Ocumension Therapeutics' (HKG:1477) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged HK$632m Last Week
Every investor in Ocumension Therapeutics (HKG:1477) should be aware of the most powerful shareholder groups. With 44% stake, private equity firms possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
As a result, private equity firms were the biggest beneficiaries of last week's 8.3% gain.
In the chart below, we zoom in on the different ownership groups of Ocumension Therapeutics.
Check out our latest analysis for Ocumension Therapeutics
SEHK:1477 Ownership Breakdown August 23rd 2022What Does The Institutional Ownership Tell Us About Ocumension Therapeutics?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Ocumension Therapeutics. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Ocumension Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:1477 Earnings and Revenue Growth August 23rd 2022Hedge funds don't have many shares in Ocumension Therapeutics. The company's largest shareholder is 6 Dimensions Capital, L.P., with ownership of 24%. With 13% and 12% of the shares outstanding respectively, Lian Yong Chen and Boyu Capital Consultancy Co., Ltd. are the second and third largest shareholders. Furthermore, CEO Ye Liu is the owner of 2.6% of the company's shares.
To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Insider Ownership Of Ocumension Therapeutics
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
It seems insiders own a significant proportion of Ocumension Therapeutics. It is very interesting to see that insiders have a meaningful HK$1.3b stake in this HK$8.2b business. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
General Public Ownership
The general public, who are usually individual investors, hold a 27% stake in Ocumension Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Equity Ownership
With an ownership of 44%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Ocumension Therapeutics you should be aware of.
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Ocumension Treateutics(HKG:1477)的每一位投资者都应该知道最强大的股东群体。私募股权公司持有44%的股份,拥有该公司最多的股份。也就是说,如果股价上涨,该集团将受益最大(如果股价下跌,该集团将损失最大)。
因此,私募股权公司是上周上涨8.3%的最大受益者。
在下面的图表中,我们放大了Ocumension治疗公司的不同所有权集团。
查看我们对Ocumension Treateutics的最新分析
联交所:1477所有权明细2022年8月23日机构所有权告诉了我们什么关于占领治疗的信息?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
如你所见,机构投资者在Ocumension Treeutics拥有相当数量的股份。这可以表明该公司在投资界具有一定的公信力。然而,最好警惕依赖机构投资者带来的所谓验证。他们也一样,有时也会犯错。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到Ocumension治疗公司的历史收益和收入,但请记住,故事总是有更多的内容。
联交所:1477盈利及收入增长2022年8月23日对冲基金在Ocumension Treateutics的股份并不多。该公司的最大股东是6Dimensions Capital,L.P.,持有24%的股份。联永晨和博裕资本咨询有限公司分别持有13%和12%的流通股,是第二大股东和第三大股东。此外,首席执行官叶刘是该公司2.6%股份的所有者。
为了让我们的研究更有趣,我们发现前四大股东控制着公司一半以上的股份,这意味着这个群体对公司的决策有相当大的影响力。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。有相当数量的分析师追踪该股,因此了解他们对未来的总体看法可能是有用的。
Ocumension治疗公司的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
内部人持股是积极的,当它标志着领导层像公司的真正所有者一样思考时。然而,高内部人持股也可以给公司内部的一个小团体带来巨大的权力。在某些情况下,这可能是负面的。
似乎内部人士拥有Ocumension Treateutics相当大的比例。非常有趣的是,内部人士在这笔82亿港元的业务中持有13亿港元的有意义的股份。大多数人会高兴地看到董事会与他们一起投资。你可能希望访问这张显示内部人士最近交易的免费图表。
一般公有制
普通公众通常是个人投资者,他们持有Ocumension Treeutics 27%的股份。虽然这群人不一定能发号施令,但它肯定能对公司的运营方式产生真正的影响。
私募股权所有权
私募股权公司拥有44%的股权,能够在塑造专注于价值创造的公司战略方面发挥作用。有时我们会看到私募股权投资长期存在,但总的来说,它们的投资期限较短,而且--顾名思义--不会对上市公司进行太多投资。一段时间后,他们可能会考虑出售并将资本重新配置到其他地方。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。一个恰当的例子:我们发现了Ocumension Treateutics的2个警告信号你应该意识到。
如果你更愿意了解分析师对未来增长的预测,请不要错过这一预期免费关于分析师预测的报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧